CHRIS J.J. MULDER; GUIDO N.J. TYTGAT; WILLEM DEKKER; IDO J. TERPSTRA
This content is PDF only. Please click on the PDF icon to access.
To the editor: 5-Aminosalicylic acid (5-ASA) is the effective moiety of sulfasalazine. The sulfapyridine moiety is usually considered to be the cause of intolerance in most of the patients who have side-effects from sulfasalazine therapy (1). Slow-release 5-ASA products have been developed, therefore, to bypass these problems. Pentasa (Gist-Brocades, the Netherlands) consists of 5-ASA microencapsulated in ethyl cellulose. Release of 5-ASA increases as the product travels down the intestine into a median with rising pH (2). We studied whether patients intolerant to sulfasalazine could tolerate Pentasa.
Seventy-one patients, aged 18 to 75 years, were entered into the study. The reasons
MULDER CJ, TYTGAT GN, DEKKER W, TERPSTRA IJ. Pentasa in Lieu of Sulfasalazine. Ann Intern Med. ;108:911–912. doi: 10.7326/0003-4819-108-6-911_2
Download citation file:
Published: Ann Intern Med. 1988;108(6):911-912.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use